Treatment with OK-432 for persistent congenital chylothorax in newborn infants resistant to octreotide.
Chylothorax is a relatively uncommon condition defined as an abnormal collection of lymphatic fluid within the pleural space. We are reporting the use of OK-432 for treatment of prolonged idiopathic congenital chylothorax in 2 newborn infants who failed to respond to conservative medical therapy, including octreotide injection.
Matsukuma
Eiji
E
The Department of Pediatrics, Nagara Medical Center, Gifu 502-8558, Japan.
Aoki
Yusuke
Y
Sakai
Miho
M
Kawamoto
Norio
N
Watanabe
Hiroh
H
Iwagaki
Shigeki
S
Takahashi
Yuichiro
Y
Kawabata
Ichiro
I
Kondo
Naomi
N
Uchida
Yasushi
Y
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D015505:Chest Tubes; D002916:Chylothorax / Q000151:congenital / Q000188:drug therapy* / Q000628:therapy; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007322:Instillation, Drug; D008297:Male; D015282:Octreotide / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D010996:Pleural Effusion / Q000188:drug therapy; D012121:Respiration, Artificial; D017211:Treatment Failure
D000970:Antineoplastic Agents; D010844:Picibanil; D002097:C-Reactive Protein; D015282:Octreotide